MedTrace Logo

Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.

NCT04260490 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2020-02-07

No results posted yet for this study

Summary

Multiple myeloma (MM) is a malignancy of plasma cells engaging in monoclonal immunoglobulin production. A strong presumption was established between exposure to pesticides and the risk of MM. The French West Indies departments of Guadeloupe and Martinique are characterized by a wide use of pesticides related to bananas plantation, particularly chlordecone which has been classified by IARC as possibly carcinogenic and has recognized hormonal properties (endocrine disruptor). The objective of this study is to measure the association between exposure to pesticide and other environmental factors in the occurrence of MM in Guadeloupe and Martinique and to estimate the proportion of cases of MM attributable to pesticide exposure. Genetic susceptibility markers and their links to environmental factors will be subsequently studies from blood samples collection.

Conditions

Sponsors & Collaborators

  • Guadeloupe Cancer Registry

    collaborator UNKNOWN

  • Martinique Cancer Registry

    collaborator UNKNOWN

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • University of Liege

    collaborator OTHER

  • University Hospital Center of Martinique

    collaborator OTHER

  • Centre Hospitalier de Basse-Terre

    collaborator UNKNOWN

  • Centre Hospitalier Universitaire de la Guadeloupe

    lead OTHER

Principal Investigators

  • Jacqueline Deloumeaux, MD · CHU de la Guadeloupe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • Guadeloupe
  • Martinique

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04260490 on ClinicalTrials.gov